Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study investigates whether chemoradiation before surgery reduces cancer cells in the blood

NCT ID NCT07194616

Knowledge-focused Sponsor: University Hospital Ostrava Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This clinical trial is looking at how chemoradiation given before surgery affects circulating tumor cells (CTCs) in patients with stage II-III rectal cancer. CTCs are cancer cells that travel in the blood and may indicate how likely the cancer is to spread. The study will compare two groups: one that gets chemoradiation followed by surgery, and another that has surgery alone. By tracking CTCs over time, researchers hope to learn more about which treatment approach might be better at controlling the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fluoropyrimidine-based chemotherapy and radiotherapy
What this could lead to
If successful, this study could help doctors understand whether chemoradiation before surgery reduces the spread of cancer cells in the bloodstream, potentially guiding better treatment decisions for rectal cancer.
What could go wrong
This is an early-stage observational trial focused on a biomarker, not a direct treatment outcome. The results may not lead to immediate changes in patient care, and the sample size is relatively small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed rectal adenocarcinoma within 12 cm from anal verge * Stage II (cT3-4 N0 M0) or stage III (cT1-4 N1-2, M0) * Negative circumferential resection margin on staging MRI * ASA physical status I-III * Signed informed consent Exclusion Criteria: * Tumor infiltration beyond fascia recti propria on MRI * Metastatic disease (stage IV) * Recurrent rectal cancer * Other concurrent malignancies * Emergency surgery required * Contraindication to surgery under general anesthesia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rectal cancer patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neoplastic Cells, Circulating rectal cancer rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rectal cancer patients

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Municipal Hospital Ostrava - Fifejdy

    RECRUITING

    Ostrava, 728 80, Czechia

  • Palacky University Olomouc, Faculty of Medicine

    RECRUITING

    Olomouc, Czechia

  • University Hospital Olomouc

    RECRUITING

    Olomouc, 779 00, Czechia

  • University Hospital Ostrava

    RECRUITING

    Ostrava, 70852, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.